Jan. 05, 2020
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
What are the inflammatory myopathies?
The inflammatory myopathies aare a group of diseases that involve chronic (long-standing) muscle inflammation, muscle weakness, and, in some cases, muscle pain. Myopathy is a general medical term used to describe a number of conditions affecting the muscles. All myopathies cause muscle weakness.
The four main types of chronic, or long-term, inflammatory myopathies are:
What causes these disorders?
Myositis, or general muscle inflammation, may be caused by:
Although the cause of many inflammatory myopathies is unknown, the majority are considered to be autoimmune disorders, in which the body’s immune response system that normally defends against infection and disease attacks its own muscle fibers, blood vessels, connective tissue, organs, or joints.
Who is at risk?
The inflammatory myopathies are rare and can affect both adults and children. Dermatomyositis is the most common chronic form in children. Polymyositis and dermatomyositis are more common in females while inclusion body myositis affects more men. Inclusion body myositis usually affects individuals over age 50.
What are the signs and symptoms?
General symptoms of chronic inflammatory myopathy include slow but progressive muscle weakness. Inflammation damages the muscle fibers, which causes weakness, and may affect the arteries and blood vessels that pass through muscle. Other symptoms include fatigue after walking or standing, frequent episodes of tripping or falling, and difficulty swallowing or breathing. Some individuals may have muscle pain or muscles that are tender to touch.
Falling and tripping are usually the first noticeable symptoms. The disorder often begins with weakness in the wrists and fingers that causes difficulty with pinching, buttoning, and gripping objects. People may experience weakness in their wrist and finger muscles and atrophy (thinning or loss of muscle bulk) in their forearm muscles and quadriceps muscles in the thighs. Difficulty swallowing occurs in approximately half of IBM cases due to involvement of the throat muscles.
Symptoms of the disease usually begin after the age of 50, although the disease can occur earlier. Unlike polymyositis and dermatomyositis, IBM occurs more frequently in men than in women.
How are the inflammatory myopathies diagnosed?
Diagnosis is based on medical history, results of a physical examination that includes tests of muscle strength, and blood samples that show elevated levels of various muscle enzymes and autoantibodies. Diagnostic tools include:
A biopsy sample of muscle tissue should be examined for signs of chronic inflammation, muscle fiber death, vascular deformities, or other changes specific to the diagnosis of a particular type of inflammatory myopathy. A skin biopsy can show changes in the skin associated with dermatomyositis.
How are these disorders treated?
Chronic inflammatory myopathies cannot be cured in most adults but many of the symptoms can be treated. Options include:
Dermatomyositis, polymyositis, and necrotizing autoimmune myopathy are first treated with high doses of corticosteroid drugs, such as prednisone. This is most often given as an oral medication but can be delivered intravenously.
Immunosuppressant drugs, such as azathioprine and methotrexate, may reduce inflammation in individuals who do not respond well to prednisone. Periodic treatment using intravenous immunoglobulin can increase the chance for recovery in individuals with dermatomyositis, polymyositis, or NAM. Other immunosuppressive agents that may treat the inflammation associated with dermatomyositis and polymyositis include cyclosporine A, cyclophosphamide, mycophenolate mofetil, and tacrolimus.
Injections of adrenocorticotropic hormone gel may be another option for people who do not respond to or cannot tolerate other drug treatment options. Biologic therapies such as rituximab or tumor necrosis factor (TNF) inhibitors such as infliximab or etanercept may be used in severe cases where other treatment options have failed. However, there are very few studies that have shown how well these agents treat polymyositis and dermatomyositis.
Physical therapy is usually recommended to prevent muscle atrophy as well as to maintain muscle strength and range of motion. Bed rest for an extended period of time should be avoided, as people may develop muscle atrophy, decreased muscle function, and joint contractures. A low-sodium diet may help to reduce edema (swelling) and cardiovascular (heart and blood vessel) complications.
Many individuals with dermatomyositis may need a topical ointment such as corticosteroids, tacrolimus, or pimecrolimus for their skin disorder. They should wear a high-protection sunscreen and protective clothing, particularly those who are light-sensitive. In rare instances, surgery may be required to remove calcium deposits that cause nerve pain and recurrent infections.
There is no standard, evidence-based course of treatment for inclusion body myositis. The disease is generally unresponsive to corticosteroids and immunosuppressive drugs. Some evidence suggests that immunosuppressive medications or intravenous immunoglobulin may have a slight, but short-lasting, beneficial effect in a small number of cases. Physical therapy may be helpful in maintaining mobility. Other therapy is symptomatic and supportive.
What is the prognosis for these diseases?
In most cases, the symptoms of dermatomyositis resolve with therapy. The disease is usually more severe and resistant to therapy in individuals with heart problems. Approximately one-third of individuals with juvenile-onset dermatomyositis recover from their illness, one-third have a relapsing-remitting course of disease, and the other third have a more chronic course of illness.
The prognosis for polymyositis varies. Most individuals respond fairly well to therapy, but some people have a more severe disease that does not. These individuals may have significant disability. Since polymyositis can cause difficulty swallowing, people can become malnourished. They are also at increased risk for falling, which can lead to hip and other bone fractures, disability, or death. In rare cases people with severe and progressive muscle weakness can develop respiratory failure or pneumonia.
Although necrotizing autoimmune myopathy is more difficult to treat than polymyositis and dermatomyositis, it generally responds well to long-term combination immunosuppressive therapies.
IBM is generally resistant to all therapies and currently available treatments do little to slow its progression.
What research is being done?
The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge of the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. NINDS is a component of the National Institutes of Health, the leading supporter of biomedical research in the world.
NINDS, along with other agencies within the National Institutes of Health (NIH), conducts and supports a wide range of research on neuromuscular disorders, including myositis and the inflammatory myopathies. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is the primary funding institute for these efforts.
One challenge in treating inflammatory myopathies is that, for some individuals, there is little direct relationship between muscle inflammation and the degree of weakness and disability. While inflammation can be slowed or reversed, muscle weakness may not respond to treatments. NIH researchers are working to identify the causes of muscle weakness in order to discover effective treatments. In addition, researchers are working to develop objective, imaging-based methods for describing the muscle damage associated with inflammatory muscle disease.
Additionally, NIH-funded researchers are studying childhood-onset polymyositis and dermatomyositis to learn more about their causes, immune system changes throughout the course of the disease, and associated medical problems. For example, scientists are studying the role of genetics in the development of juvenile dermatomyositis. Researchers are examining the genetic differences between sets of twins in order to identify the relationship between genes and dermatomyositis that may lead to potential new treatment methods for the condition.
Currently, there are no therapies approved by the U.S. Food and Drug Administration for diagnosing inflammatory myopathies. NIH-funded researchers are looking for better, less invasive ways of diagnosing these disorders. For example, researchers are developing a non-invasive test that diagnoses IBM using circulating RNA molecules in the blood or urine. Researchers hope that this test will help clinicians identify individuals with IBM and assist them in monitoring their responses to clinical therapeutic trials.
Scientists are testing if the drug sodium thiosulfate can treat calcium buildup seen in people with juvenile and adult dermatomyositis. Other NIH-funded researchers are studying the genetic diversity disease susceptibility in the inflammatory myopathies. Researchers from the National Institute of Environmental Health Sciences (NIEHS) are evaluating possible contributing causes, including dietary supplements, tobacco smoke, and infectious agents. Other researchers are also investigating the impact of certain drugs on muscle inflammation. For example, NIH researchers are exploring the impact of autoimmune muscle disease triggered by statins.
More information about research on myositis and the inflammatory myopathies supported by NINDS and other NIH Institutes and Centers may be found using NIH RePORTER, a searchable database of current and past research projects supported by NIH and other Federal agencies. RePORTER also includes links to publications and resources from these projects.
Where can I get more information?
For more information on neurological disorders or research programs funded by the National Institute of Neurological Disorders and Stroke, contact the Institute's Brain Resources and Information Network (BRAIN) at:
P.O. Box 5801
Bethesda, MD 20824
Information also is available from the following organizations:
American Autoimmune Related Diseases Association
22100 Gratiot Avenue
Eastpointe, MI 48021-2227
Tel: 586-776-3900; 800-598-4668
P.O. Box 7669
Atlanta, GA 30357
Tel: 800-283-7800; 404-872-7100; 404-965-7888
1737 King Street
Alexandria, VA 22314
Tel: 703-299-4850; 800-821-7356
Muscular Dystrophy Association
National Office - 222 S. Riverside Plaza
Chicago, IL 60606
National Institute of Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse
1 AMS Circle
Bethesda, MD 20892-3675
Tel: 877-22-NIAMS (226-4267); 301-565-2966 (TTY)
National Institute of Environmental Health Sciences (NIEHS)
National Institutes of Health, DHHS
111 T.W. Alexander Drive
Research Triangle Park, NC 27709
U.S. National Library of Medicine
National Institutes of Health/DHHS
8600 Rockville Pike
Bethesda, MD 20894
"Inflammatory Myopathies Fact Sheet", NINDS, Publication date January 2020. NIH Publication No. 20-NS-5321
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied.
The information in this document is for general educational purposes only. It is not intended to substitute for personalized professional advice. Although the information was obtained from sources believed to be reliable, MedLink, its representatives, and the providers of the information do not guarantee its accuracy and disclaim responsibility for adverse consequences resulting from its use. For further information, consult a physician and the organization referred to herein.